OR WAIT null SECS
May 28, 2020
Merck will use Themis’s vector platform to develop a vaccine to prevent COVID-19.
Merck will acquire Themis Bioscience and collaborate with IAVI and Ridgeback Bio on COVID-19 vaccines and therapies.
CordenPharma and Moderna extended a strategic manufacturing services agreement for the supply of lipid excipients to be used in Moderna’s vaccine against SARS-CoV-2.
May 26, 2020
The 60,000-ft2 facility will work in conjunction with the company’s Kakegawa, Japan, clinical supply facility to serve local and global biotech and pharmaceutical companies.
The companies have entered into a partnership worth more than $231 million to provide GSK with added capacity to manufacture and supply its biopharmaceutical therapies.
May 22, 2020
Funding from the US government could lead to 300 million coronavirus vaccine doses by October 2020.
May 21, 2020
The companies have formed a collaboration to develop a novel human recombinant protein as a therapeutic candidate against COVID-19.
CanSinoBIO will license-in Precision NanoSystems' proprietary RNA vaccine platform technology while the latter leads the development of the RNA vaccine formulation.
May 18, 2020
Ori Biotech is partnering with manufacturers and materials suppliers to develop an automated system for cell and gene therapy manufacturing.
May 14, 2020
The Center for iPS Cell Research and Application Foundation and the Cell and Gene Therapy Catapult have announced the launch of a new collaborative research project that will focus on induced pluripotent stem cell characterization.